Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LeMaitre Vascular, Inc. - Common Stock (NQ:LMAT)

83.66 +0.81 (+0.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about LeMaitre Vascular, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
1 Cash-Heavy Stock with Impressive Fundamentals and 2 We Question
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
1 Reason LMAT is Risky and 1 Stock to Buy Instead
LeMaitre currently trades at $83.37 per share and has shown little upside over the past six months, posting a middling return of 2.9%. The stock also fell short of the S&P 500’s 15.6% gain during that... 
Via StockStory
Topics Stocks Supply Chain
News headline image
LeMaitre (LMAT) Q3 2025 Earnings Call Transcript ↗
LeMaitre (LMAT) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
3 Healthcare Stocks We Steer Clear Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but... 
Via StockStory
Topics Stocks
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. 
Via StockStory
Topics Economy
News headline image
LeMaitre Vascular Inc (NASDAQ:LMAT) Stands Out as a Quality Investment Using the Caviar Cruise Screen ↗
LeMaitre Vascular (LMAT) is a high-quality medical device company with strong revenue & EBIT growth, a 32.83% ROIC, and a solid financial profile. 
Via Chartmill
News headline image
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
Via StockStory
News headline image
5 Must-Read Analyst Questions From LeMaitre’s Q3 Earnings Call
LeMaitre’s third quarter results drew a negative market reaction as revenue trailed Wall Street expectations, despite solid year-over-year growth. Management cited strong performances from the Grafts... 
Via StockStory
Topics Earnings
News headline image
LMAT Q3 Deep Dive: Pricing and Margin Expansion Offset by Cautious Growth Outlook
Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance of... 
Via StockStory
News headline image
LeMaitre (NASDAQ:LMAT) Reports Sales Below Analyst Estimates In Q3 Earnings
Medical device company LeMaitre Vascular (NASDAQ:LMAT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 11.4% year on year to $61.05 million. Next quarter’s revenue guidance... 
Via StockStory
News headline image
LeMaitre Earnings: What To Look For From LMAT
Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be reporting results this Thursday after the bell. Here’s what investors should know. 
Via StockStory
News headline image
3 Cash-Producing Stocks We Think Twice About
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Where LeMaitre Vascular Stands With Analysts ↗
 
Via Benzinga
News headline image
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Surgical Equipment & Consumables - Specialty Stocks Q2 Earnings Review: LeMaitre (NASDAQ:LMAT) Shines
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including LeMaitre (NASDAQ:LMAT) and its peers. 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
1 High-Flying Stock with Solid Fundamentals and 2 We Ignore
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
News headline image
Healthcare Staffing Giant AMN Healthcare Soars Amidst Landmark Drug-Pricing Agreement
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a... 
Via MarketMinute
Topics Government
News headline image
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing... 
Via MarketMinute
Topics Economy Government World Trade
News headline image
AbbVie, AMN Healthcare Services, LeMaitre, Waters Corporation, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. 
Via StockStory
Topics Government
News headline image
3 Reasons LMAT is Risky and 1 Stock to Buy Instead
Since March 2025, LeMaitre has been in a holding pattern, posting a small return of 1.8% while floating around $85.45. The stock also fell short of the S&P 500’s 18.6% gain during that period. 
Via StockStory
Topics Stocks Supply Chain
News headline image
Integra LifeSciences and LeMaitre Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics World Trade
News headline image
1 Profitable Stock with Solid Fundamentals and 2 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
LeMaitre Vascular Inc. (NASDAQ:LMAT) Exemplifies Quality Investing Principles in Caviar Cruise Screen ↗
LeMaitre Vascular (LMAT) exemplifies quality investing with strong revenue growth, a 32.83% ROIC, and robust cash flow. A top pick from the Caviar Cruise screen for durable, high-quality stocks. 
Via Chartmill
News headline image
Astrana Health, Privia Health, Illumina, Waters Corporation, and LeMaitre Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy
News headline image
Why LeMaitre (LMAT) Stock Is Down Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) fell 2.2% in the afternoon session after the stock traded lower amid broader market weakness. U.S. stock markets began September trading... 
Via StockStory
Topics Bonds Stocks World Trade
News headline image
LMAT Q2 Deep Dive: International Expansion and Product Momentum Drive Upbeat Outlook
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 15% year on year to $64.23 million. Guidance for next... 
Via StockStory
News headline image
Why LeMaitre (LMAT) Stock Is Trading Up Today
Shares of medical device company LeMaitre Vascular (NASDAQ:LMAT) jumped 9.5% in the afternoon session after the company reported better-than-expected second-quarter financial results and raised its... 
Via StockStory
Topics ETFs Stocks World Trade
News headline image
LeMaitre (LMAT) Q2 Revenue Jumps 15% ↗
Via The Motley Fool
News headline image
LeMaitre (NASDAQ:LMAT) Exceeds Q2 Expectations, Full-Year Sales Guidance is Optimistic
Medical device company LeMaitre Vascular (NASDAQ:LMAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15% year on year to $64.23 million. Guidance for next quarter’s... 
Via StockStory
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.